Abstract
Monoclonal IgM anti-myelin-associated glycoprotein (MAG) antibody-related peripheral neuropathy (anti-MAG neuropathy) is predominantly a demyelinating sensory neuropathy with ataxia and distal paresthesia. The clinical course of anti-MAG neuropathy is usually slowly progressive making difficult the identification of clear criteria to start a specific treatment. Although no consensus treatment is yet available, a rituximab-based regimen targeting the B-cell clone producing the monoclonal IgM may be proposed, alone or in combination with alkylating agents or purine analogs. However, in some rare cases, an acute and severe neurological deterioration can occur in few days leading to a rapid loss of autonomy. In these cases, a treatment rapidly removing the monoclonal IgM from the circulation might be useful before initiating a specific therapy. We report successful treatment with plasma exchanges (PE) in four patients presenting with acute neurological deterioration. PE allowed a dramatic and rapid neurological improvement in all patients. PE are safe and may be useful at the initial management of these cases of anti-MAG neuropathy.
Similar content being viewed by others
References
Steck AJ, Stalder AK, Renaud S (2006) Anti-myelin-associated glycoprotein neuropathy. Curr Opin Neurol 19:458–463. doi:10.1097/01.wco.0000245368.36576.0d
Viala K, Stojkovic T, Doncker A-V et al (2012) Heterogeneous spectrum of neuropathies in Waldenström’s macroglobulinemia: a diagnostic strategy to optimize their management. J Peripher Nerv Syst 17:90–101
Iancu Ferfoglia R, Guimarães-Costa R, Viala K et al (2016) Long-term efficacy of rituximab in IgM anti-myelin-associated glycoprotein neuropathy: RIMAG follow-up study. J Peripher Nerv Syst 21:10–14
Lunn MP, Nobile-Orazio E (2016) Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev 10:CD002827. doi:10.1002/14651858.CD002827.pub4
Owen RG, Pratt G, Auer RL et al (2014) Guidelines on the diagnosis and management of Waldenström macroglobulinaemia. Br J Haematol 165:316–333. doi:10.1111/bjh.12760
Lunn MPT, Nobile-Orazio E (2012) Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev 5:CD002827. doi:10.1002/14651858.CD002827.pub3
Oksenhendler E, Chevret S, Léger JM et al (1995) Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM-associated Polyneuropathy Study Group. J Neurol Neurosurg Psychiatry 59:243–247
Owen RG, Kyle RA, Stone MJ et al (2013) Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. Br J Haematol 160:171–176. doi:10.1111/bjh.12102
Willison HJ, Trapp BD, Bacher JD et al (1988) Demyelination induced by intraneural injection of human antimyelin-associated glycoprotein antibodies. Muscle Nerve 11:1169–1176. doi:10.1002/mus.880111111
Brown WF, Feasby TE (1984) Conduction block and denervation in Guillain–Barré polyneuropathy. Brain J Neurol 107(Pt 1):219–239
Sala E, Robert-Varvat F, Paul S et al (2014) Acute neurological worsening after rituximab treatment in patients with anti-MAG neuropathy. J Neurol Sci 345:224–227. doi:10.1016/j.jns.2014.07.055
Broglio L, Lauria G (2005) Worsening after rituximab treatment in anti-mag neuropathy. Muscle Nerve 32:378–379. doi:10.1002/mus.20386
Gironi M, Saresella M, Ceresa L et al (2006) Clinical and immunological worsening in a patient affected with Waldenstrom macroglobulinemia and anti-mag neuropathy after treatment with rituximab. Haematologica 91(4):e51–e52
Ghobrial IM, Fonseca R, Greipp PR et al (2004) Initial immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer 101:2593–2598. doi:10.1002/cncr.20658
Zucca E, Conconi A, Laszlo D et al (2013) Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study. J Clin Oncol 31:565–572. doi:10.1200/JCO.2011.40.6272
Author information
Authors and Affiliations
Contributions
S.H., M.V., M.M., B.A., D.B., N.P., and J.P.F. contributed to patients’ information collection; P.L. and N.B. contributed to conception of the work and critical revision of the article; and M.B. and B.A. contributed to conception of the work and wrote the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
All authors: no reported conflicts.
Ethics approval
Approved by local ethic committee.
Informed consent
All persons gave their informed consent.
Rights and permissions
About this article
Cite this article
Baron, M., Lozeron, P., Harel, S. et al. Plasma exchanges for severe acute neurological deterioration in patients with IgM anti-myelin-associated glycoprotein (anti-MAG) neuropathy. J Neurol 264, 1132–1135 (2017). https://doi.org/10.1007/s00415-017-8502-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-017-8502-3